U.S. patent application number 11/596786 was filed with the patent office on 2007-10-18 for polypeptides for inducing a protective immune response against staphylococcus aureus.
Invention is credited to Annaliesa S. Anderson.
Application Number | 20070243205 11/596786 |
Document ID | / |
Family ID | 35451336 |
Filed Date | 2007-10-18 |
United States Patent
Application |
20070243205 |
Kind Code |
A1 |
Anderson; Annaliesa S. |
October 18, 2007 |
Polypeptides for Inducing a Protective Immune Response Against
Staphylococcus Aureus
Abstract
The present invention features polypeptides comprising an amino
acid sequence structurally related to SEQ ID NO: 1 and uses of such
polypeptides. SEQ ID NO: 1 is a derivative of a full length S.
aureus polypeptide. The full-length naturally occurring polypeptide
is referred to herein as full length "ORF0826". The SEQ ID NO: 1
derivative contains an alanine addition after the initial
methionine. A His-tag derivative of SEQ ID NO: 1 was found to
produce a protective immune response against S. aureus.
Inventors: |
Anderson; Annaliesa S.;
(Doylestown, PA) |
Correspondence
Address: |
MERCK AND CO., INC
P O BOX 2000
RAHWAY
NJ
07065-0907
US
|
Family ID: |
35451336 |
Appl. No.: |
11/596786 |
Filed: |
May 20, 2005 |
PCT Filed: |
May 20, 2005 |
PCT NO: |
PCT/US05/17835 |
371 Date: |
November 16, 2006 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60574032 |
May 25, 2004 |
|
|
|
Current U.S.
Class: |
424/190.1 ;
435/252.33; 435/70.2; 530/350; 536/23.7 |
Current CPC
Class: |
A61P 31/04 20180101;
C07K 14/31 20130101; A61K 39/00 20130101 |
Class at
Publication: |
424/190.1 ;
435/252.33; 435/070.2; 530/350; 536/023.7 |
International
Class: |
A61K 39/085 20060101
A61K039/085; C07H 21/00 20060101 C07H021/00; C07K 14/31 20060101
C07K014/31; C12N 1/21 20060101 C12N001/21; C12P 21/04 20060101
C12P021/04 |
Claims
1. A polypeptide immunogen comprising an amino acid sequence at
least 85% identical to SEQ ID NO: 1, wherein the polypeptide is not
SEQ ID NOs: 3, 4, or 5, wherein said polypeptide provides
protective immunity against S. aureus.
2. The polypeptide of claim 1, wherein said amino acid sequence is
at least 95% identical to SEQ ID NO: 1.
3. The polypeptide of claim 2, wherein said amino acid sequence
consists essentially of amino acids 3-167 of SEQ ID NO: 1.
4. The polypeptide of claim 1, wherein said polypeptide consists of
the amino acid sequence of SEQ ID NO: 1, amino acids 2-167 of SEQ
ID NO: 1, or amino acids 3-167 of SEQ ID NO: 1.
5. An immunogen comprising an amino acid sequence at least 85%
identical to SEQ ID NO: 1, and one or more additional regions
moieties covalently joined to said amino acid sequence at the
carboxyl terminus or amino terminus, wherein each region or moiety
is independently selected from a region or moiety having at least
one of the following properties: enhances the immune response,
facilitates purification, or facilitates polypeptide stability.
6. A composition able to induce a protective immune response in a
patient comprising an immunologically effective amount of the
immunogen of claim 1, and a pharmaceutically acceptable
carrier.
7. The composition of claim 6, wherein said composition further
comprises an adjuvant.
8. A nucleic acid comprising a recombinant gene comprising a
nucleotide sequence encoding the polypeptide of a polypeptide
immunogen comprising an amino acid sequence at least 85% identical
to SEQ ID NO: 1, wherein the polypeptide is not SEQ ID NOs: 3, 4,
or 5, wherein said polypeptide provides protective immunity against
S. aureus.
9. The nucleic acid of claim 8, wherein said nucleic acid is an
expression vector.
10. A recombinant cell comprising a recombinant gene comprising the
nucleic acid of claim 8.
11. A method of making a S. aureus polypeptide that provides
protective immunity comprising the steps of: (a) growing the
recombinant cell of claim 10 under conditions wherein said
polypeptide is expressed; and (b) purifying said polypeptide.
12. A method of inducing a protective immune response in a patient
comprising the step of administering to said patient an
immunologically effective amount of the immunogen of claim 1.
13. The method of claim 12, wherein said patient is a human.
14. The method of claim 13, wherein said patient is treated
prophylactically against S. aureus infection.
15. A method of inducing a protective immune response in a patient
comprising the step of administering to said patient an
immunologically effective amount of a polypeptide made by the
method of claim 11.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims the benefit of U.S.
Provisional Application No. 60/574,032, filed May 25, 2004 hereby
incorporated by reference herein.
BACKGROUND OF THE INVENTION
[0002] The references cited throughout the present application are
not admitted to be prior art to the claimed invention.
[0003] Staphylococcus aureus is a pathogen responsible for a wide
range of diseases and conditions. Examples of diseases and
conditions caused by S. aureus include bacteremia, infective
endocarditis, folliculitis, furuncle, carbuncle, impetigo, bullous
impetigo, cellulitis, botryomyosis, toxic shock syndrome, scalded
skin syndrome, central nervous system infections, infective and
inflammatory eye disease, osteomyletitis and other infections of
joints and bones, and respiratory tract infections. (The
Staphylococci in Human Disease, Crossley and Archer (eds.),
Churchill Livingstone Inc. 1997.)
[0004] Immunological based strategies can be employed to control S.
aureus infections and the spread of S. aureus. Immunological based
strategies include passive and active immunization. Passive
immunization employs immunoglobulins targeting S. aureus. Active
immunization induces immune responses against S. aureus.
[0005] Potential S. aureus vaccines target S. aureus
polysaccharides and polypeptides. Targeting can be achieved using
suitable S. aureus polysaccharides or polypeptides as vaccine
components. Examples of polysaccharides that may be employed as
possible vaccine components include S. aureus type 5 and type 8
capsular polysaccharides. (Shinefield et al., N. Eng. J. Med.
346:491-496, 2002.) Examples of polypeptides that may be employed
as possible vaccine components include collagen adhesin, fibrinogen
binding proteins, and clumping factor. (Mamo et al., FEMS
Immunology and Medical Microbiology 10:47-54, 1994, Nilsson et al.,
J. Clin. Invest. 101:2640-2649, 1998, Josefsson et al., The Journal
of Infectious Diseases 184:1572-1580, 2001.)
[0006] Information concerning S. aureus polypeptide sequences has
been obtained from sequencing the S. aureus genome. (Kuroda et al.,
Lancet 357:1225-1240, 2001, Baba et al., Lancet 359:1819-1827,
2000, Kunsch et al., European Patent Publication EP 0 786 519,
published Jul. 30, 1997.) To some extent bioinformatics has been
employed in efforts to characterize polypeptide sequences obtained
from genome sequencing. (Kunsch et al., European Patent Publication
EP 0 786 519, published Jul. 30, 1997.)
[0007] Techniques such as those involving display technology and
sera from infected patients can be used in an effort to identify
genes coding for potential antigens. (Foster et al., International
Publication Number WO 01/98499, published Dec. 27, 2001, Meinke et
al., International Publication Number WO 02/059148, published Aug.
1, 2002, Etz et al., PNAS 99:6573-6578, 2002.)
SUMMARY OF THE INVENTION
[0008] The present invention features polypeptides comprising an
amino acid sequence structurally related to SEQ ID NO: 1 and uses
of such polypeptides. SEQ ID NO: 1 is a derivative of a full length
S. aureus polypeptide. The full-length naturally occurring
polypeptide is referred to herein as full length "ORF0826". The SEQ
ID NO: 1 derivative contains an alanine addition after the initial
methionine. A His-tag derivative of SEQ ID NO: 1 was found to
produce a protective immune response against S. aureus.
[0009] Reference to "protective" immunity or immune response
indicates a detectable level of protection against S. aureus
infection. The level of protection can be assessed using animal
models such as those described herein.
[0010] Thus, a first aspect of the present invention describes a
polypeptide immunogen comprising an amino acid sequence at least
85% identical to SEQ ID NO: 1, wherein the polypeptide is not SEQ
ID NO: 3, SEQ ID NO: 4, or SEQ ID NO: 5. Reference to immunogen
indicates the ability to provide protective immunity against S.
aureus.
[0011] Reference to comprising an amino acid sequence at least 85%
identical to SEQ ID NO: 1 indicates that a SEQ ID NO: 1 related
region is present and additional polypeptide regions may be
present. Polypeptides of SEQ ID NO: 3, SEQ ID NO: 4, or SEQ ID NO:
5, fall within the 85% identity, but are excluded from the first
aspect of the invention.
[0012] Percent identity (also referred to as percent identical) to
a reference sequence is determined by aligning the polypeptide
sequence with the reference sequence and determining the number of
identical amino acids in the corresponding regions. This number is
divided by the total number of amino acids in the reference
sequence (e.g., SEQ ID NO: 1) and then multiplied by 100 and
rounded to the nearest whole number.
[0013] Another aspect of the present invention describes an
immunogen comprising a polypeptide that provides protective
immunity against S. aureus and one or more additional regions or
moieties covalently joined to the polypeptide at the carboxyl
terminus or amino terminus, wherein each region or moiety is
independently selected from a region or moiety having at least one
of the following properties: enhances the immune response,
facilitates purification, or facilitates polypeptide stability.
[0014] Reference to "additional region or moiety" indicates a
region or moiety different from a ORF0826 region. The additional
region or moiety can be, for example, an additional polypeptide
region or a non-peptide region.
[0015] Another aspect of the present invention describes a
composition able to induce protective immunity against S. aureus in
a patient. The composition comprises a pharmaceutically acceptable
carrier and an immunologically effective amount of a polypeptide
that provides protective immunity against S. aureus.
[0016] An immunologically effective amount is an amount sufficient
to provide protective immunity against S. aureus infection. The
amount should be sufficient to significantly prevent the likelihood
or severity of a S. aureus infection.
[0017] Another aspect of the present invention describes a nucleic
acid comprising a recombinant gene encoding a polypeptide that
provides protective immunity against S. aureus. A recombinant gene
contains recombinant nucleic acid encoding a polypeptide along with
regulatory elements for proper transcription and processing (which
may include translational and post translational elements). The
recombinant gene can exist independent of a host genome or can be
part of a host genome.
[0018] A recombinant nucleic acid is nucleic acid that by virtue of
its sequence and/or form does not occur in nature. Examples of
recombinant nucleic acid include purified nucleic acid, two or more
nucleic acid regions combined together that provides a different
nucleic acid than found in nature, and the absence of one or more
nucleic acid regions (e.g., upstream or downstream regions) that
are naturally associated with each other.
[0019] Another aspect of the present invention describes a
recombinant cell. The cell comprises a recombinant gene encoding a
polypeptide that provides protective immunity against S.
aureus.
[0020] Another aspect of the present invention describes a method
of making a polypeptide that provides protective immunity against
S. aureus. The method involves growing a recombinant cell
containing recombinant nucleic acid encoding the polypeptide and
purifying the polypeptide.
[0021] Another aspect of the present invention describes a
polypeptide that provides protective immunity against S. aureus
made by a process comprising the steps of growing a recombinant
cell containing recombinant nucleic acid encoding the polypeptide
in a host and purifying the polypeptide. Different host cells can
be employed.
[0022] Another aspect of the present invention describes a method
of inducing a protective immune response in a patient against S.
aureus. The method comprises the step of administering to the
patient an immunologically effective amount of a polypeptide that
provides protective immunity against S. aureus or an immunogen
containing the protective polypeptide.
[0023] Unless particular terms are mutually exclusive, reference to
"or" indicates either or both possibilities. Occasionally phrases
such as "and/or" are used to highlight either or both
possibilities.
[0024] Reference to open-ended terms such as "comprises" allows for
additional elements or steps. Occasionally phrases such as "one or
more" are used with or without open-ended terms to highlight the
possibility of additional elements or steps.
[0025] Unless explicitly stated reference to terms such as "a" or
"an" is not limited to one. For example, "a cell" does not exclude
"cells". Occasionally phrases such as one or more are used to
highlight the possible presence of a plurality.
[0026] Other features and advantages of the present invention are
apparent from the additional descriptions provided herein including
the different examples. The provided examples illustrate different
components and methodology useful in practicing the present
invention. The examples do not limit the claimed invention. Based
on the present disclosure the skilled artisan can identify and
employ other components and methodology useful for practicing the
present invention.
BRIEF DESCRIPTION OF THE DRAWINGS
[0027] FIG. 1 illustrates the amino acid sequence of SEQ ID NO: 1
and SEQ ID NO: 2. The entire sequence is SEQ ID NO: 2. The portion
shown in bold is SEQ ID NO: 1. The underlined regions is a His-tag
region added to SEQ ID NO: 1.
[0028] FIG. 2 illustrate a sequence comparison between SEQ ID NO: 1
(SEQ 1) SEQ ID NO: 3 (SEQ 3), SEQ ID NO: 4 (SEQ 4), SEQ ID NO: 5
(SEQ 5), SEQ ID NO: 6 (SEQ 6), and SEQ ID NO: 7 (SEQ 7). Amino acid
differences are shown in bold.
[0029] FIG. 3 illustrates a nucleic acid sequence (SEQ ID NO: 8)
encoding SEQ ID NO: 2. The region encoding SEQ ID NO: 1 is shown in
bold. The His-tag region and a GCC alanine codon are
underlined.
[0030] FIG. 4 illustrates a nucleic acid sequence encoding ORF0826
(SEQ ID NO: 9).
[0031] FIGS. 5A, 5B, and 5C illustrate results from different
experiments using a SEQ ID NO: 2 polypeptide in aluminum
hydroxyphosphate adjuvant (ABP). The polypeptide is referred to as
"SEQ 2".
DETAILED DESCRIPTION OF THE INVENTION
[0032] The ability of SEQ ID NO: 1 related polypeptides to provide
protective immunity is illustrated in the Examples provided below
using SEQ ID NO: 2. SEQ ID NO: 2 is a His-tag derivative of SEQ ID
NO: 1. The His-tag facilitates polypeptide purification and
identification.
[0033] SEQ ID NO: 1 is a derivative of a full length S. aureus
polypeptide designated ORF0826. Polypeptides structurally related
to SEQ ID NO: 1 include polypeptides containing corresponding
regions present in different S. aureus strains and derivatives of
naturally occurring regions. The amino acid sequence of SEQ ID NO:
1 is illustrated by the bold region FIG. 1. FIG. 1 also illustrates
a His-tag region present in SEQ ID NO: 2.
ORF0826 Sequences
[0034] ORF0826 related sequences have been given different
designations in different references. Examples of different
designations are provided in Kuroda et al., Lancet 357:1225-1240,
2001 (SAV23049 and SA2097); Baba et al., Lancet 359:1819-1827, 2002
(MW2222); and Etz et al., Proc. Natl. Acad. Sci. USA
99(10):6573-6578, 2002 (SA2295).
[0035] ORF0826 shares a high degree of homology with S. epidermidis
secreted antigen Ssa. Ssa is described in Lang et al., FEMS
Immunology and Medical Microbiology 29:213-220, 2000.
[0036] A polypeptide sequence corresponding to an ORF0826 related
sequence appears to be provided in different patent publications.
(Meinke et al., International Publication Number WO 02/059148,
published Aug. 1, 2002, and Masignani et al., International
Publication Number WO 02/094868, published Nov. 28, 2002.)
[0037] FIG. 2 provides a sequence comparison of different ORF0826
related sequences. SEQ ID NO: 3 is a methicillan resistant S.
aureus (obtained by searching nucleic acid sequence data deposited
at www.sanger.ac.uk), SEQ ID NO: 4 corresponds to WO 02/059148
sequence identifier number 73, SEQ ID NO: 5 corresponds to WO
02/094868 sequence identifier number 782, and SEQ ID NOs: 6 and 7
are additional naturally occurring sequences.
[0038] Other naturally occurring ORF0826 sequences can be
identified based on the presence of a high degree of sequence
similarity or contiguous amino acids compared to a known ORF0826
sequence. Contiguous amino acids provide characteristic tags. In
different embodiments, a naturally occurring ORF0826 sequence is a
sequence found in a Staphylococcus, preferably S. aureus, having at
least 20, at least 30, or at least 50 contiguous amino acids as in
SEQ ID NO: 1; and/or having at least 85% sequence similarity or
identity with SEQ ID NO: 1.
[0039] Sequence similarity can be determined by different
algorithms and techniques well known in the art. Generally,
sequence similarity is determined by techniques aligning two
sequences to obtain maximum amino acid identity, allowing for gaps,
additions and substitutions in one of the sequences.
[0040] Sequence similarity can be determined, for example, using a
local alignment tool utilizing the program lalign (developed by
Huang and Miller, Adv. Appl. Math. 12:337-357, 1991, for the
<<sim>>program). The options and environment variables
are:-f # Penalty for the first residue a gap (-14 by default); -g #
Penalty for each additional residue in a gap (-4 by default)-s str
(SMATRIX) the filename of an alternative scoring matrix file. For
protein sequences, PAM250 is used by default-w # (LINLEN) output
line length for sequence alignments (60).
SEQ ID NO: 1 Related Polypeptides
[0041] SEQ ID NO: 1 related polypeptides contain an amino acid
sequence at least 85% identical to SEQ ID NO: 1. Reference to
"polypeptide" does not provide a minimum or maximum size
limitation.
[0042] A polypeptide at least 85% identical to SEQ ID NO: 1
contains up to about 25 amino acid alterations from SEQ ID NO: 1.
In different embodiments, the SEQ ID NO: 1 related polypeptide is
at least 90%, at least 94%, or at least 99% identical to SEQ ID NO:
1; differs from SEQ ID NO: 1 by 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10,
11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid alterations;
or consists essentially of amino acids 2-167 of SEQ ID NO: 1. Each
amino acid alteration is independently either an addition,
substitution or deletion.
[0043] Reference to "consists essentially" of indicated amino acids
indicates that the referred to amino acids are present and
additional amino acids may be present. The additional amino acids
can be at the carboxyl or amino terminus. In different embodiments
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
or 20 additional amino acids are present. A preferred additional
amino acid is an amino terminus methionine.
[0044] Alterations can be made to SEQ ID NO: 1 to obtain
derivatives that can induce protective immunity against S. aureus.
Alterations can be performed, for example, to obtain a derivative
retaining the ability to induce protective immunity against S.
aureus or to obtain a derivative that in addition to providing
protective immunity also has a region that can achieve a particular
purpose.
[0045] The sequence comparison provided in FIG. 2 can be used to
help guide the design of potential alterations to SEQ ID NO: 1. In
addition, alterations can be made taking into account other ORF0826
sequences and known properties of amino acids.
[0046] Generally, in substituting different amino acids to retain
activity it is preferable to exchange amino acids having similar
properties. Factors that can be taken into account for an amino
acid substitution include amino acid size, charge, polarity, and
hydrophobicity. The effect of different amino acid R-groups on
amino acid properties are well known in the art. (See, for example,
Ausubel, Current Protocols in Molecular Biology, John Wiley,
1987-2002, Appendix 1C.)
[0047] In exchanging amino acids to maintain activity, the
replacement amino acid should have one or more similar properties
such as approximately the same charge and/or size and/or polarity
and/or hydrophobicity. For example, substituting valine for
leucine, arginine for lysine, and asparagine for glutamine are good
candidates for not causing a change in polypeptide functioning.
[0048] Alterations to achieve a particular purpose include those
designed to facilitate production or efficacy of the polypeptide;
or cloning of the encoded nucleic acid. Polypeptide production can
be facilitated through the use of an initiation codon (e.g., coding
for methionine) suitable for recombinant expression. The methionine
may be later removed during cellular processing. Cloning can be
facilitated by, for example, the introduction of restriction sites
which can be accompanied by amino acid additions or changes.
[0049] Efficacy of a polypeptide to induce an immune response can
be enhanced through epitope enhancement. Epitope enhancement can be
performed using different techniques such as those involving
alteration of anchor residues to improve peptide affinity for MHC
molecules and those increasing affinity of the peptide-MHC complex
for a T-cell receptor. (Berzofsky et al., Nature Review 1:209-219,
2001.)
[0050] Preferably, the polypeptide is a purified polypeptide. A
"purified polypeptide" is present in an environment lacking one or
more other polypeptides with which it is naturally associated
and/or is represented by at least about 10% of the total protein
present. In different embodiments, the purified polypeptide
represents at least about 50%, at least about 75%, or at least
about 95% of the total protein in a sample or preparation.
[0051] In an embodiment, the polypeptide is "substantially
purified." A substantially purified polypeptide is present in an
environment lacking all, or most, other polypeptides with which the
polypeptide is naturally associated. For example, a substantially
purified S. aureus polypeptide is present in an environment lacking
all, or most, other S. aureus polypeptides. An environment can be,
for example, a sample or preparation.
[0052] Reference to "purified" or "substantially purified" does not
require a polypeptide to undergo any purification and may include,
for example, a chemically synthesized polypeptide that has not been
purified.
[0053] Polypeptide stability can be enhanced by modifying the
polypeptide carboxyl or amino terminus. Examples of possible
modifications include amino terminus protecting groups such as
acetyl, propyl, succinyl, benzyl, benzyloxycarbonyl or
t-butyloxycarbonyl; and carboxyl terninus protecting groups such as
amide, methylamide, and ethylamide.
[0054] In an embodiment of the present invention the polypeptide
immunogen is part of an immunogen containing one or more additional
regions or moieties covalently joined to the polypeptide at the
carboxyl terminus or amino terminus, where each region or moiety is
independently selected from a region or moiety having at least one
of the following properties: enhances the immune response,
facilitates purification, or facilitates polypeptide stability.
Polypeptide stability can be enhanced, for example, using groups
such as polyethylene glycol that may be present on the amino or
carboxyl terminus.
[0055] Polypeptide purification can be enhanced by adding a group
to the carboxyl or amino terminus to facilitate purification.
Examples of groups that can be used to facilitate purification
include polypeptides providing affinity tags. Examples of affinity
tags include a six-histidine tag, trpE, glutathione and
maltose-binding protein.
[0056] The ability of a polypeptide to produce an immune response
can be enhanced using groups that generally enhance an immune
response. Examples of groups that can be joined to a polypeptide to
enhance an immune response against the polypeptide include
cytokines such as IL-2. (Buchan et al., 2000. Molecular Immunology
37:545-552.)
Polypeptide Production
[0057] Polypeptides can be produced using standard techniques
including those involving chemical synthesis and those involving
purification from a cell producing the polypeptide. Techniques for
chemical synthesis of polypeptides are well known in the art. (See
e.g., Vincent, Peptide and Protein Drug Delivery, New York, N. Y.,
Decker, 1990.) Techniques for recombinant polypeptide production
and purification are also well known in the art. (See for example,
Ausubel, Current Protocols in Molecular Biology, John Wiley,
1987-2002.)
[0058] Obtaining polypeptides from a cell is facilitated using
recombinant nucleic acid techniques to produce the polypeptide.
Recombinant nucleic acid techniques for producing a polypeptide
involve introducing, or producing, a recombinant gene encoding the
polypeptide in a cell and expressing the polypeptide.
[0059] A recombinant gene contains nucleic acid encoding a
polypeptide along with regulatory elements for polypeptide
expression. The recombinant gene can be present in a cellular
genome or can be part of an expression vector.
[0060] The regulatory elements that may be present as part of a
recombinant gene include those naturally associated with the
polypeptide encoding sequence and exogenous regulatory elements not
naturally associated with the polypeptide encoding sequence.
Exogenous regulatory elements such as an exogenous promoter can be
useful for expressing a recombinant gene in a particular host or
increasing the level of expression. Generally, the regulatory
elements that are present in a recombinant gene include a
transcriptional promoter, a ribosome binding site, a terminator,
and an optionally present operator. A preferred element for
processing in eukaryotic cells is a polyadenylation signal.
[0061] Expression of a recombinant gene in a cell is facilitated
through the use of an expression vector. Preferably, an expression
vector in addition to a recombinant gene also contains an origin of
replication for autonomous replication in a host cell, a selectable
marker, a limited number of useful restriction enzyme sites, and a
potential for high copy number. Examples of expression vectors are
cloning vectors, modified cloning vectors, specifically designed
plasmids and viruses.
[0062] Due to the degeneracy of the genetic code, a large number of
different encoding nucleic acid sequences can be used to code for a
particular polypeptide. The degeneracy of the genetic code arises
because almost all amino acids are encoded by different
combinations of nucleotide triplets or "codons". Amino acids are
encoded by codons as follows: [0063] A=Ala=Alanine: codons GCA,
GCC, GCG, GCU [0064] C=Cys=Cysteine: codons UGC, UGU [0065]
D=Asp=Aspartic acid: codons GAC, GAU [0066] E=Glu=Glutamic acid:
codons GAA, GAG [0067] F=Phe=Phenylalanine: codons UUC, UUU [0068]
G=Gly=Glycine: codons GGA, GGC, GGG, GGU [0069] H=His=Histidine:
codons CAC, CAU [0070] I=Ile=Isoleucine: codons AUA, AUC, AUU
[0071] K=Lys=Lysine: codons AAA, AAG [0072] L=Leu=Leucine: codons
UUA, UUG, CUA, CUC, CUG, CUU [0073] M=Met=Methionine: codon AUG
[0074] N=Asn=Asparagine: codons AAC, AAU [0075] P=Pro=Proline:
codons CCA, CCC, CCG, CCU [0076] Q=Gln=Glutamine: codons CAA, CAG
[0077] R=Arg=Arginine: codons AGA, AGG, CGA, CGC, CGG, CGU [0078]
S=Ser=Serine: codons AGC, AGU, UCA, UCC, UCG, UCU [0079]
T=Thr=Threonine: codons ACA, ACC, ACG, ACU [0080] V=Val=Valine:
codons GUA, GUC, GUG, GUU [0081] W=Trp=Tryptophan: codon UGG [0082]
Y=Tyr=Tyrosine: codons UAC, UAU
[0083] Suitable cells for recombinant nucleic acid expression of
SEQ ID NO: 1 related polypeptides are prokaryotes and eukaryotes.
Examples of prokaryotic cells include E. coli; members of the
Staphylococcus genus, such as S. aureus; members of the
Lactobacillus genus, such as L. plantarum; members of the
Lactococcus genus, such as L. lactis; and members of the Bacillus
genus, such as B. subtilis. Examples of eukaryotic cells include
mammalian cells; insect cells; yeast cells such as members of the
Saccharomyces genus (e.g., S. cerevisiae), members of the Pichia
genus (e.g., P. pastoris), members of the Hanseizula genus (e.g.,
H. polymorpha), members of the Kluyveromyces genus (e.g., K. lactis
or K. fragilis) and members of the Schizosaccharomyces genus (e.g.,
S. pombe).
[0084] Techniques for recombinant gene production, introduction
into a cell, and recombinant gene expression are well known in the
art. Examples of such techniques are provided in references such as
Ausubel, Current Protocols in Molecular Biology, John Wiley,
1987-2002, and Sambrook et al., Molecular Cloning, A Laboratory
Manual, 2.sup.nd Edition, Cold Spring Harbor Laboratory Press,
1989.
[0085] If desired, expression in a particular host can be enhanced
through codon optimization. Codon optimization includes use of more
preferred codons. Techniques for codon optimization in different
hosts are well known in the art.
[0086] SEQ ID NO: 1 related polypeptides may contain post
translational modifications, for example, N-linked glycosylation,
O-linked glycosylation, or acetylation. Reference to "polypeptide"
or an "amino acid" sequence of a polypeptide includes polypeptides
containing one or more amino acids having a structure of a
post-translational modification from a host cell, such as a yeast
host.
[0087] Post translational modifications can be produced chemically
or by making use of suitable hosts. For example, in S. cerevisiae
the nature of the penultimate amino acid appears to determine
whether the N-terminal methionine is removed. Furthermore, the
nature of the penultimate amino acid also determines whether the
N-terminal amino acid is N.sup..alpha.-acetylated (Huang et al.,
Biochemistry 26: 8242-8246, 1987). Another example includes a
polypeptide targeted for secretion due to the presence of a
secretory leader (e.g., signal peptide), where protein is modified
by N-linked or O-linked glycosylation. (Kukuruzinska et al., Ann.
Rev. Biochem. 56:915-944, 1987.)
Adjuvants
[0088] Adjuvants are substances that can assist an immunogen in
producing an immune response. Adjuvants can function by different
mechanisms such as one or more of the following: increasing the
antigen biologic or immunologic half-life; improving antigen
delivery to antigen-presenting cells; improving antigen processing
and presentation by antigen-presenting cells; and inducing
production of immunomodulatory cytokines. (Vogel, Clinical
Infectious Diseases 30(suppl. 3):S266-270, 2000.)
[0089] A variety of different types of adjuvants can be employed to
assist in the production of an immune response. Examples of
particular adjuvants include aluminum hydroxide, aluminum
phosphate, or other salts of aluminum, calcium phosphate, DNA CpG
motifs, monophosphoryl lipid A, cholera toxin, E. coli heat-labile
toxin, pertussis toxin, muramyl dipeptide, Freund's incomplete
adjuvant, MF59, SAF, immunostimulatory complexes, liposomes,
biodegradable microspheres, saponins, nonionic block copolymers,
muramyl peptide analogues, polyphosphazene, synthetic
polynucleotides, IFN-.gamma., IL-2 and IL-12. (Vogel Clinical
Infectious Diseases 30(suppl 3):S266-270, 2000, Klein et al.,
Journal of Pharmaceutical Sciences 89:311-321, 2000.)
Patients For Inducing Protective Immunity
[0090] A "patient" refers to a mammal capable of being infected
with S. aureus. A patient can be treated prophylactically or
therapeutically. Prophylactic treatment provides sufficient
protective immunity to reduce the likelihood, or severity, of a S.
aureus infection. Therapeutic treatment can be performed to reduce
the severity of a S. aureus infection.
[0091] Prophylactic treatment can be performed using a vaccine
containing an immunogen described herein. Such treatment is
preferably performed on a human. Vaccines can be administered to
the general population or to those persons at an increased risk of
S. aureus infection.
[0092] Persons with an increased risk of S. aureus infection
include health care workers; hospital patients; patients with a
weakened immune system; patients undergoing surgery; patients
receiving foreign body implants, such a catheter or a vascular
device; patients facing therapy leading to a weakened immunity; and
persons in professions having an increased risk of burn or wound
injury. (The Staphylococci in Human Disease, Crossley and Archer
(ed.), Churchill Livingstone Inc. 1997.)
[0093] Non-human patients that can be infected with S. aureus
include cows, pigs, sheep, goats, rabbits, horses, dogs, cats and
mice. Treatment of non-human patients is useful in protecting pets
and livestock, and in evaluating the efficacy of a particular
treatment.
Combination Vaccines
[0094] SEQ ID NO: 1 related polypeptides can be used alone, or in
combination with other immunogens, to induce an immune response.
Additional immunogens that may be present include: one or more
additional S. aureus immunogens, such as those referenced in the
Background of the Invention supra; one or more immunogens targeting
one or more other Staphylococcus organisms such as S. epidermidis,
S. haemolyticus, S. wameri, or S. lugunensis; and one or more
immunogens targeting other infections organisms.
Animal Model System
[0095] An animal model system was used to evaluate the efficacy of
an immunogen to produce a protective immune response against
Staphylococcus. Two obstacles encountered in setting up a
protective animal model were: (1) very high challenge dose needed
to overcome innate immunity and (2) death rate too fast to detect a
protective response. Specifically, after bacterial challenge mice
succumbed to infection within 24 hours which did not provide
sufficient time for the specific immune responses to resolve the
infection. If the dose was lowered both control and immunized mice
survived the infection.
[0096] These obstacles were addressed by using a slow kinetics
lethality model involving Staphylococcus prepared from cells in
stationary phase, appropriately titrated, and intravenously
administered. This slow kinetics of death provides sufficient time
for the specific immune defense to fight off the bacterial
infection (e.g., 10 days rather 24 hours).
[0097] Staphylococcus cells in stationary phase can be obtained
from cells grown on solid medium. They can also be obtained from
liquid, however the results with cells grown on solid media were
more reproducible. Cells can conveniently be grown overnight on
solid medium. For example, S. aureus can be grown from about 18 to
about 24 hours under conditions where the doubling time is about
20-30 minutes.
[0098] Staphylococcus can be isolated from solid or liquid medium
using standard techniques to maintain Staphylococcus potency.
Isolated Staphylococcus can be stored, for example, at -70.degree.
C. as a washed high density suspension (>10.sup.9 colony forming
units (CFU)/mL) in phosphate buffered saline containing
glycerol.
[0099] The Staphylococcus challenge should have a potency providing
about 80 to 90% death in an animal model over a period of about 7
to 10 days starting on the first or second day. Titration
experiments can be performed using animal models to monitor the
potency of the stored Staphylococcus inoculum. The titration
experiments can be performed about one to two weeks prior to an
inoculation experiment.
[0100] Initial potency for titration experiments can be based on
previous experiments. For S. aureus and the animal model strain
Becker a suitable potency was generally found in the range of
5.times.10.sup.8 to 8.times.10.sup.8 CFU/ml.
Administration
[0101] Immunogens can be formulated and administered to a patient
using the guidance provided herein along with techniques well known
in the art. Guidelines for pharmaceutical administration in general
are provided in, for example, Vaccines Eds. Plotkin and Orenstein,
W. B. Sanders Company, 1999; Remington's Pharmaceutical Sciences
20.sup.th Edition, Ed. Gennaro, Mack Publishing, 2000; and Modem
Pharmaceutics 2.sup.nd Edition, Eds. Banker and Rhodes, Marcel
Dekker, Inc., 1990, each of which are hereby incorporated by
reference herein.
[0102] Pharmaceutically acceptable carriers facilitate storage and
administration of an immunogen to a patient. Pharmaceutically
acceptable carriers may contain different components such as a
buffer, sterile water for injection, normal saline or phosphate
buffered saline, sucrose, histidine, salts and polysorbate.
[0103] Immunogens can be administered by different routes such as
subcutaneous, intramuscular, or mucosal. Subcutaneous and
intramuscular administration can be performed using, for example,
needles or jet-injectors.
[0104] Suitable dosing regimens are preferably determined taking
into account factors well known in the art including age, weight,
sex and medical condition of the patient; the route of
administration; the desired effect; and the particular compound
employed. The immunogen can be used in multi-dose vaccine formats.
It is expected that a dose would consist of the range of 1.0 .mu.g
to 1.0 mg total polypeptide, in different embodiments of the
present invention the range is 0.01 mg to 1.0 mg and 0.1 mg to 1.0
mg.
[0105] The timing of doses depends upon factors well known in the
art. After the initial administration one or more booster doses may
subsequently be administered to maintain or boost antibody titers.
An example of a dosing regime would be day 1, 1 month, a third dose
at either 4, 6 or 12 months, and additional booster doses at
distant times as needed.
Generation of Antibodies
[0106] A SEQ ID NO: 1 related polypeptide can be used to generate
antibodies and antibody fragments that bind to the polypeptide or
to S. aureus. Such antibodies and antibody fragments have different
uses including use in polypeptide purification, S. aureus
identification, or in therapeutic or prophylactic treatment against
S. aureus infection.
[0107] Antibodies can be polyclonal or monoclonal. Techniques for
producing and using antibodies are well known in the art. Examples
of such techniques are described in Ausubel, Current Protocols in
Molecular Biology, John Wiley, 1987-2002, Harlow et al.,
Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory,
1988, and Kohler et al., Nature 256:495-497, 1975.
EXAMPLES
[0108] Examples are provided below further illustrating different
features of the present invention. The examples also illustrate
useful methodology for practicing the invention. These examples do
not limit the claimed invention.
Example 1
Protective Immunity
[0109] This example illustrates the ability of SEQ ID NO: 1 related
polypeptides to provide protective immunity in an animal model. SEQ
ID NO: 2, a His-tag derivative of SEQ ID NO: 1, was used to provide
protective immunity.
SEQ ID NO: 2 Cloning and Expression
[0110] The protein was designed to be expressed from the pET30
vector with the terminal His residues encoded by the vector. In
addition, an alanine residue was added to the protein after the
methionine initiator. The designed DNA sequence encodes a 211 amino
acid altered form of mature ORF0826.
[0111] An ORF0826 DNA sequence (SEQ ID NO: 9) was translated using
Vector NTI software and the resulting 167 amino acid sequence (SEQ
ID NO: 4) was analyzed. PCR primers were designed to amplify the
gene starting at the first lysine residue and ending prior to the
stop codon at the terminal isoleucine residue. The forward PCR
primers had an additional NcoI restriction site to facilitate
cloning into the expression vector, they also included a methionine
codon followed by an alanine codon to ensure in frame expression of
the protein. The reverse PCR primer included a XhoI restriction
site to facilitate cloning into the expression vector and a stop
codon.
[0112] PCR amplified sequences digested with NcoI and XhoI then
ligated into the pET30 vector (Novagen) using the NcoI/XhoI sites
that had been engineered into the PCR primers and introduced into
E. coli DH5.alpha. (Invitrogen) by heat shock. Colonies were
selected, grown in LB with 30 .mu.g/mL kanamycin, DNA minipreps
made (Promega), and insert integrity determined by restriction
digestion and PCR. A clone was selected containing no DNA changes
from the desired sequence.
[0113] E. coli HMS174(DE3) cells (Novagen) were transformed and
grown on LB plates containing kanamycin (30 ug/ml). Liquid LB
(kanamycin) cultures were set up by inoculating with single
colonies from the LB (kanamycin) plates and incubated at 37.degree.
C., 250 rpm until the A.sub.600 was between 0.6 and 1.0 and then
induced by the addition of IPTG to final concentrations of 1 mM
followed by three hours further incubation. Cultures were harvested
by centrifugation at 5000.times.g for 5 minutes at 4.degree. C.
Cells were resuspended in 500 .mu.l lysis buffer (Bugbuster, with
protease inhibitors, Novagen). An equal volume of loading buffer
(supplemented with .beta.-mecapto ethanol to 5% final volume) was
added prior to heating the samples at 70.degree. C. for 5 minutes.
Extracts were run on Novex 4-20% Tris-Glycine gels and assayed for
protein (Coomassie Blue stained) and blotted onto nitrocellulose
and probed with anti-HIS6 antibodies (Zymed).
SEQ ID NO: 2 Purification
[0114] Frozen recombinant E. coli cell paste (17.3 grams) was
thawed and resuspended in 100 ml Lysis Buffer (50 mM Tris-HCl, pH
8.0 at 20.degree. C.+2 mM magnesium chloride, 10 mM imidazole, 0.1%
Tween-80, 0.15 M NaCl, 100 uL Benzonase (25,000 Units), 1 ml
protease inhibitors (Sigma # P-8849), and 100 mg lysozyme). A
lysate was prepared with a microfluidizer at .about.14,000 psi. The
lysate was clarified by centrifugation at 11,000.times.g for 20
minutes at 4.degree. C. The pellet was washed twice with TBS (0.15
M NaCl in 2,0 mM Tris-HCl, pH 8.0), and resuspended in 8 M urea in
TBS to solubilize the proteins from the pellet. The urea-soluble
protein solution was mixed with Ni-NTA agarose chromatography resin
(Qiagen #30250) and stirred for one hour at room temperature.
[0115] The slurry of chromatography resin in urea-soluble protein
solution was poured into a chromatography column and the non-bound
fraction was collected by gravity from the column outlet. The resin
was washed with TBS, and the column was eluted with Elution Buffer
(0.3 M imidazole, 0.15 M NaCl, 20 mM Tris-HCl, pH 7.5, +0.1%
Tween-80). Fractions containing the protein product were identified
by SDS/PAGE with Coomassie staining and pooled. The Pooled
fractions from the Ni-NTA agarose column were filtered through a
Zeta Plus.RTM. BioCap.TM. filter (CUNO #BC003OA9OSP). The filtrate
was dialyzed vs. Dialysis Buffer (20 mM Tris-HCl, pH 7.5, 0.15 M
NaCl, 0.1% Tween-80) in a 10,000 MWCO Slide-A-Lyzer.TM. dialysis
cassette (Pierce). The dialyzed product was sterile-filtered. The
sterile-filtered product was adsorbed on aluminum hydroxyphosphate
adjuvant at a final concentration of 0.2 mg/ml. The remainder of
the sterile-filtered product was snap-frozen in liquid nitrogen for
long-term storage at -70.degree. C.
Preparation of S. aureus Challenge
[0116] S. aureus was grown on TSA plates at 37.degree. C.
overnight. The bacteria were washed from the TSA plates by adding 5
ml of PBS onto a plate and gently resuspending the bacteria with a
sterile spreader. The bacterial suspension was spun at 6000 rpm for
20 minutes using a Sorvall RC-5B centrifuge (DuPont Instruments).
The pellet was resuspended in 16% glycerol and aliquots were stored
frozen at -70.degree. C.
[0117] Prior to use, inocula were thawed, appropriately diluted and
used for infection. Each stock was titrated at least 3 times to
determine the appropriate dose inducing slow kinetics of death in
naive mice. The potency of the bacterial inoculum (80 to 90%
lethality) was constantly monitored to assure reproducibility of
the model. Ten days before each challenge experiment, a group of 10
control animals (immunized with adjuvant alone) were challenged and
monitored.
Protection Studies for a SEQ ID NO: 2 Polypeptide
[0118] Three different protection studies were performed using (1)
25 BALB/c mice, (2) 20 BALB/c mice, and (3) 20 BALB/c mice. The
mice were immunized with three doses of a SEQ ID NO: 2 polypeptide
(20 .mu.g per dose) on aluminum hydroxyphosphate adjuvant (450
.mu.g per dose). Aluminum hydroxyphosphate adjuvant (AHP) is
described by Klein et al., Journal of Phannaceutical Sciences 89,
311-321, 2000. The doses were administered as two 50 .mu.l
injections intramuscularly on days 0, 7 and 21. The mice were bled
on day 28, and their sera were screened by ELSIA for reactivity to
an antibody recognizing SEQ ID NO: 2.
[0119] On day 35 of the experiment the mice were challenged with S.
aureus (10.sup.8 CFU ml) and evaluated against a control set of the
same number of mice that had just been immunized with AHP. The mice
were monitored for survival.
[0120] The results are shown in FIGS. 5A, 5B and 5C. In the first
experiment (FIG. 5A), 9 out of 25 immunized mice survived compared
to 3 out of 25 surviving in the AHP control group. In the second
experiment (FIG. 5B), using 20 immunized and 20 control mice, no
increased protection compared to the control was observed. In the
third experiment (FIG. 5C), 8 out of 20 immunized mice survived
compared to 6 out of 30 in the AHP control group.
[0121] The second experiment was considered a null experiment, due
to the high numbers of mice surviving in the control AHP group (13
mice). Null experiments are sometimes seen due to the difficulty in
running this model which is dependent on the quantity and quality
of the bacteria used for the challenge.
[0122] Other embodiments are within the following claims. While
several embodiments have been shown and described, various
modifications may be made without departing from the spirit and
scope of the present invention.
Sequence CWU 1
1
9 1 167 PRT Artificial Sequence ORF0826 derivative containing an
alanine addition after the initial methionine 1 Met Ala Lys Lys Leu
Val Thr Ala Thr Thr Leu Thr Ala Gly Ile Gly 1 5 10 15 Thr Ala Leu
Val Gly Gln Ala Tyr His Ala Asp Ala Ala Glu Asn Tyr 20 25 30 Thr
Asn Tyr Asn Asn Tyr Asn Tyr Asn Thr Thr Gln Thr Thr Thr Thr 35 40
45 Thr Thr Thr Thr Thr Thr Thr Ser Ser Ile Ser His Ser Gly Asn Leu
50 55 60 Tyr Thr Ala Gly Gln Cys Thr Trp Tyr Val Tyr Asp Lys Val
Gly Gly 65 70 75 80 Glu Ile Gly Ser Thr Trp Gly Asn Ala Asn Asn Trp
Ala Ala Ala Ala 85 90 95 Gln Gly Ala Gly Phe Thr Val Asn His Thr
Pro Ser Lys Gly Ala Ile 100 105 110 Leu Gln Ser Ser Glu Gly Pro Phe
Gly His Val Ala Tyr Val Glu Ser 115 120 125 Val Asn Ser Asp Gly Ser
Val Thr Ile Ser Glu Met Asn Tyr Ser Gly 130 135 140 Gly Pro Phe Ser
Val Ser Ser Arg Thr Ile Ser Ala Ser Glu Ala Gly 145 150 155 160 Asn
Tyr Asn Tyr Ile His Ile 165 2 211 PRT Artificial Sequence a His-tag
derivative of SEQ ID NO 1 2 Met His His His His His His Ser Ser Gly
Leu Val Pro Arg Gly Ser 1 5 10 15 Gly Met Lys Glu Thr Ala Ala Ala
Lys Phe Glu Arg Gln His Met Asp 20 25 30 Ser Pro Asp Leu Gly Thr
Asp Asp Asp Asp Lys Ala Met Ala Lys Lys 35 40 45 Leu Val Thr Ala
Thr Thr Leu Thr Ala Gly Ile Gly Thr Ala Leu Val 50 55 60 Gly Gln
Ala Tyr His Ala Asp Ala Ala Glu Asn Tyr Thr Asn Tyr Asn 65 70 75 80
Asn Tyr Asn Tyr Asn Thr Thr Gln Thr Thr Thr Thr Thr Thr Thr Thr 85
90 95 Thr Thr Thr Ser Ser Ile Ser His Ser Gly Asn Leu Tyr Thr Ala
Gly 100 105 110 Gln Cys Thr Trp Tyr Val Tyr Asp Lys Val Gly Gly Glu
Ile Gly Ser 115 120 125 Thr Trp Gly Asn Ala Asn Asn Trp Ala Ala Ala
Ala Gln Gly Ala Gly 130 135 140 Phe Thr Val Asn His Thr Pro Ser Lys
Gly Ala Ile Leu Gln Ser Ser 145 150 155 160 Glu Gly Pro Phe Gly His
Val Ala Tyr Val Glu Ser Val Asn Ser Asp 165 170 175 Gly Ser Val Thr
Ile Ser Glu Met Asn Tyr Ser Gly Gly Pro Phe Ser 180 185 190 Val Ser
Ser Arg Thr Ile Ser Ala Ser Glu Ala Gly Asn Tyr Asn Tyr 195 200 205
Ile His Ile 210 3 162 PRT S. aureus 3 Met Lys Lys Leu Val Thr Ala
Thr Thr Leu Thr Ala Gly Ile Gly Thr 1 5 10 15 Ala Leu Val Gly His
Ala Gln His Ala Asp Ala Ala Glu Asn Tyr Thr 20 25 30 Asn Tyr Asn
Tyr Asn Thr Thr Gln Thr Thr Thr Thr Thr Thr Thr Thr 35 40 45 Thr
Thr Thr Ser Ser Ile Ser His Ser Gly Asn Leu Tyr Thr Ala Gly 50 55
60 Gln Cys Thr Trp Tyr Val Tyr Asp Lys Val Gly Gly Glu Ile Gly Ser
65 70 75 80 Thr Trp Gly Asn Ala Asn Asn Trp Ala Ala Ala Ala Gln Gly
Ala Gly 85 90 95 Phe Thr Val Asn His Thr Pro Ser Lys Gly Ala Ile
Leu Gln Ser Ser 100 105 110 Glu Gly Pro Phe His Val Ala Tyr Val Glu
Ser Val Asn Ser Asp Gly 115 120 125 Ser Val Thr Ile Ser Glu Met Asn
Tyr Ser Gly Gly Pro Phe Ser Val 130 135 140 Ser Ser Arg Thr Ile Ser
Ala Ser Glu Ala Gly Asn Tyr Asn Tyr Ile 145 150 155 160 His Ile 4
166 PRT S. aureus 4 Met Lys Lys Leu Val Thr Ala Thr Thr Leu Thr Ala
Gly Ile Gly Thr 1 5 10 15 Ala Leu Val Gly Gln Ala Tyr His Ala Asp
Ala Ala Glu Asn Tyr Thr 20 25 30 Asn Tyr Asn Asn Tyr Asn Tyr Asn
Thr Thr Gln Thr Thr Thr Thr Thr 35 40 45 Thr Thr Thr Thr Thr Thr
Ser Ser Ile Ser His Ser Gly Asn Leu Tyr 50 55 60 Thr Ala Gly Gln
Cys Thr Trp Tyr Val Tyr Asp Lys Val Gly Gly Glu 65 70 75 80 Ile Gly
Ser Thr Trp Gly Asn Ala Asn Asn Trp Ala Ala Ala Ala Gln 85 90 95
Gly Ala Gly Phe Thr Val Asn His Thr Pro Ser Lys Gly Ala Ile Leu 100
105 110 Gln Ser Ser Glu Gly Pro Phe Gly His Val Ala Tyr Val Glu Ser
Val 115 120 125 Asn Ser Asp Gly Ser Val Thr Ile Ser Glu Met Asn Tyr
Ser Gly Gly 130 135 140 Pro Phe Ser Val Ser Ser Arg Thr Ile Ser Ala
Ser Glu Ala Gly Asn 145 150 155 160 Tyr Asn Tyr Ile His Ile 165 5
166 PRT S. aureus 5 Met Lys Lys Leu Val Thr Ala Thr Thr Leu Thr Ala
Gly Ile Gly Thr 1 5 10 15 Ala Leu Val Gly Gln Ala His His Ala Asp
Ala Ala Glu Asn Tyr Thr 20 25 30 Asn Tyr Asn Asn Tyr Asn Tyr Asn
Thr Thr Gln Thr Thr Thr Thr Thr 35 40 45 Thr Thr Thr Thr Thr Thr
Ser Ser Ile Ser His Ser Gly Asn Leu Tyr 50 55 60 Thr Ala Gly Gln
Cys Thr Trp Tyr Val Tyr Asp Lys Val Gly Gly Glu 65 70 75 80 Ile Gly
Ser Thr Trp Gly Asn Ala Asn Asn Trp Ala Ala Ala Ala Gln 85 90 95
Gly Ala Gly Phe Thr Val Asn His Thr Pro Ser Lys Gly Ala Ile Leu 100
105 110 Gln Ser Ser Glu Gly Pro Phe Gly His Val Ala Tyr Val Glu Ser
Val 115 120 125 Asn Ser Asp Gly Ser Val Thr Ile Ser Glu Met Asn Tyr
Ser Gly Gly 130 135 140 Pro Phe Ser Val Ser Ser Arg Thr Ile Ser Ala
Ser Glu Ala Gly Asn 145 150 155 160 Tyr Asn Tyr Ile His Ile 165 6
166 PRT S. aureus 6 Gly Gln Lys Leu Val Thr Ala Thr Thr Leu Thr Ala
Gly Ile Gly Thr 1 5 10 15 Ala Leu Val Gly Gln Ala His His Ala Asp
Ala Ala Glu Asn Tyr Thr 20 25 30 Asn Tyr Asn Asn Tyr Asn Tyr Asn
Thr Thr Gln Thr Thr Thr Thr Thr 35 40 45 Thr Thr Thr Thr Thr Thr
Ser Ser Ile Ser His Ser Gly Asn Leu Tyr 50 55 60 Thr Ala Gly Gln
Cys Thr Trp Tyr Val Tyr Asp Lys Val Gly Gly Glu 65 70 75 80 Ile Gly
Ser Thr Trp Gly Asn Ala Asn Asn Trp Ala Ala Ala Ala Gln 85 90 95
Gly Ala Gly Phe Thr Val Asn His Thr Pro Ser Lys Gly Ala Ile Leu 100
105 110 Gln Ser Ser Glu Gly Pro Phe Gly His Val Ala Tyr Val Glu Ser
Val 115 120 125 Asn Ser Asp Gly Ser Val Thr Ile Ser Glu Met Asn Tyr
Ser Gly Gly 130 135 140 Pro Phe Ser Val Ser Ser Arg Thr Ile Ser Ala
Ser Glu Ala Gly Asn 145 150 155 160 Tyr Asn Tyr Ile His Ile 165 7
161 PRT S. aureus 7 Met Lys Lys Leu Val Thr Ala Thr Thr Leu Thr Ala
Gly Ile Gly Thr 1 5 10 15 Ala Leu Val Gly Gln Val His His Ala Asp
Ala Ala Glu Asn Tyr Thr 20 25 30 Asn Tyr Asn Asn Tyr Asn Tyr Asn
Thr Thr Thr Thr Thr Thr Thr Thr 35 40 45 Thr Ser Ser Ile Ser His
Ser Gly Asn Leu Tyr Thr Ala Gly Gln Cys 50 55 60 Thr Trp Tyr Val
Tyr Asp Lys Val Gly Gly Glu Ile Gly Ser Thr Trp 65 70 75 80 Gly Asn
Ala Asn Asn Trp Ala Ala Ala Ala Gln Gly Ala Gly Phe Thr 85 90 95
Val Asn His Thr Pro Ser Lys Gly Ala Ile Leu Gln Ser Ser Glu Gly 100
105 110 Pro Phe Gly His Val Ala Tyr Val Glu Ser Val Asn Ser Asp Gly
Ser 115 120 125 Val Thr Ile Ser Glu Met Asn Tyr Ser Gly Gly Pro Phe
Ser Val Ser 130 135 140 Ser Arg Thr Ile Ser Ala Ser Glu Ala Gly Asn
Tyr Asn Tyr Ile His 145 150 155 160 Ile 8 636 DNA Artificial
Sequence nucleic acid sequence encoding SEQ ID NO 2 8 atgcaccatc
atcatcatca ttcttctggt ctggtgccac gcggttctgg tatgaaagaa 60
accgctgctg ctaaattcga acgccagcac atggacagcc cagatctggg taccgacgac
120 gacgacaagg ccatggccaa aaaattagta acagcaacta cgttaacagc
aggaatcggc 180 acagcattag taggtcaagc atatcatgca gatgctgctg
aaaattatac aaattacaac 240 aactataact acaacacgac tcaaactaca
acgactacga caactacgac aactacatca 300 tcaatttcac attctggtaa
cttatacact gcaggacaat gtacttggta tgtatatgat 360 aaagttggcg
gagaaatcgg ttctacttgg ggaaatgcta ataattgggc tgctgctgca 420
caaggtgctg gattcacagt aaatcataca ccttctaaag gcgctatcct acaatcttct
480 gaaggaccat ttggtcacgt tgcatatgta gaaagtgtaa acagtgatgg
ttcagttaca 540 atttcagaaa tgaattatag tggcggacct ttctcagtaa
gttctagaac tatttctgca 600 agtgaagcag gtaactacaa ctacatccat atttaa
636 9 498 DNA Artificial Sequence cDNA encoding ORF0826 9
atgaaaaaat tagtaacagc aactacgtta acagcaggaa tcggcacagc attagtaggt
60 caagcatatc atgcagatgc tgctgaaaat tatacaaatt acaacaacta
taactacaac 120 acgactcaaa ctacaacgac tacgacaact acgacaacta
catcatcaat ttcacattct 180 ggtaacttat acactgcagg acaatgtact
tggtatgtat atgataaagt tggcggagaa 240 atcggttcta cttggggaaa
tgctaataat tgggctgctg ctgcacaagg tgctggattc 300 acagtaaatc
atacaccttc taaaggcgct atcctacaat cttctgaagg accatttggt 360
cacgttgcat atgtagaaag tgtaaacagt gatggttcag ttacaatttc agaaatgaat
420 tatagtggcg gacctttctc agtaagttct agaactattt ctgcaagtga
agcaggtaac 480 tacaactaca tccatatt 498
* * * * *
References